Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
Rituximab showed no clear difference in death at 6 months compared with cyclophosphamide (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Rituximab showed no clear difference in remission at 6 months compared with cyclophosphamide (moderate certainty).
Rituximab showed no clear difference in relapse at 12 months compared with cyclophosphamide (low certainty).
Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
Rituximab showed no clear difference in serious Infections compared with cyclophosphamide (moderate certainty).
Mycophenolate mofetil showed no clear difference in death at 6 months compared with cyclophosphamide (low certainty).
The review found no eligible studies for this question.
Mycophenolate mofetil showed no clear difference in dialysis compared with cyclophosphamide (low certainty).
Mycophenolate mofetil showed no clear difference in relapse at any time point compared with cyclophosphamide (low certainty).
Mycophenolate mofetil probably leads to higher remission at 6 months compared with cyclophosphamide (moderate certainty).
Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).
Mycophenolate mofetil showed no clear difference in infection compared with cyclophosphamide (moderate certainty).
Azathioprine showed no clear difference in death (median compared with cyclophosphamide (moderate certainty).
The review found no eligible studies for this question.
Azathioprine showed no clear difference in dialysis (median compared with cyclophosphamide (moderate certainty).